CEO Interview: Roche Pharma Head Daniel O'Day On R&D Strategy
In an interview with Scrip, Roche Pharma CEO Daniel O'Day emphasized the importance that personalized healthcare will have in transforming R&D and how patients are treated.
You may also be interested in...
By picking up the rest of Foundation Medicine, which is now valued at $5.3bn, the Swiss giant is expanding its leadership in cancer diagnostics, genomics and molecular information for personal medicine.
Buying Flatiron Health offers research-quality electronic medical records data which will help gain access to patients and help in the drug development and reimbursement process, Roche exes say.
Phase II data for antibody-drug conjugate polatuzumab vedotin in diffuse large B cell lymphoma suggest potential for a cure if the drug were given up front, Roche says on investor call after American Society of Hematology meeting.